Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Bioventus stock

Learn how to easily invest in Bioventus stock.

Bioventus is a medical devices business based in the US. Bioventus shares (BVS) are listed on the NASDAQ and all prices are listed in US Dollars. Bioventus employs 1,160 staff and has a trailing 12-month revenue of around $516.7 million.

How to buy Bioventus stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – BVS. It's that simple.

Best for beginners

Finder Award


  • Trade stocks and ETFs for $0 and no annual fee
  • Minimum deposit of $10 required
  • Get $10 when you sign up and deposit $100

Promoted for easy user experience


  • Commission-free trading
  • Commission-free crypto
  • No minimum account balance

Best for low fees

Finder Award

SoFi Invest

  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Bioventus stock price (NASDAQ: BVS)

Use our graph to track the performance of BVS stocks over time.

Bioventus shares at a glance

Information last updated 2023-01-24.
Latest market close$2.06
52-week range$1.65 - $15.10
50-day moving average $2.47
200-day moving average $7.01
Wall St. target price$6.50
PE ratio 11.4444
Dividend yield $0 (0%)
Earnings per share (TTM) $0.18

Buy Bioventus stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, Options, ETFs, Cryptocurrency
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Stocks, Options, ETFs, Cryptocurrency
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Stocks, ETFs, Cryptocurrency, Alternatives
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
Winner of Finder’s Best Overall Stock Broker award.

Compare up to 4 providers

*Signup bonus information updated weekly.

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Bioventus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Bioventus price performance over time

Historical closes compared with the close of $2.06 from 2023-01-24

1 week (2023-01-19) -7.21%
1 month (2022-12-23) -18.90%
3 months (2022-10-26) -72.24%
6 months (2022-07-26) -74.38%
1 year (2022-01-26) -83.83%
2 years (2021-01-22) N/A
3 years (2020-01-22) N/A
5 years (2018-01-22) N/A

Is Bioventus stock undervalued or overvalued?

Valuing Bioventus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bioventus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Bioventus's P/E ratio

Bioventus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, Bioventus shares trade at around 11x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Bioventus's P/E ratio is best considered in relation to those of others within the medical devices industry or those of similar companies.

Bioventus's PEG ratio

Bioventus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.1421. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bioventus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider Bioventus's PEG ratio in relation to those of similar companies.

Bioventus's EBITDA

Bioventus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $25.6 million.

The EBITDA is a measure of a Bioventus's overall financial performance and is widely used to measure a its profitability.

To put Bioventus's EBITDA into context you can compare it against that of similar companies.

Bioventus financials

Revenue TTM $516.7 million
Gross profit TTM $302.7 million
Return on assets TTM -1.07%
Return on equity TTM -55.9%
Profit margin -24.61%
Book value $5.56
Market capitalisation $127.6 million

TTM: trailing 12 months

Bioventus share dividends

We're not expecting Bioventus to pay a dividend over the next 12 months.

You may also wish to consider:

Bioventus overview

Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Frequently asked questions

What percentage of Bioventus is owned by insiders or institutions?
Currently 15.644% of Bioventus shares are held by insiders and 70.284% by institutions.
How many people work for Bioventus?
Latest data suggests 1,160 work at Bioventus.
When does the fiscal year end for Bioventus?
Bioventus's fiscal year ends in December.
Where is Bioventus based?
Bioventus's address is: 4721 Emperor Boulevard, Durham, NC, United States, 27703
What is Bioventus's ISIN number?
Bioventus's international securities identification number is: US09075A1088

More guides on Finder

Ask an Expert provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site